Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

InfanDx AG. (4/24/19). "Press Release: InfanDx AG Closes 5.3 Mio EUR Financing". Cologne & Bonn.

Organisations Organisation InfanDx AG
  Organisation 2 LSI Pre-SeedFonds GmbH
  Group Life Science Inkubator GmbH (LSI)
Products Product diagnostic test, rapid (point-of-care)
  Product 2 venture capital
Index term Index term InfanDx–SEVERAL: investment, 201904 financing round up to €5.3m milestone-based from Bamed MAM + CVG Capital + LSI PreSeed + Arnika Beteiligungen
Persons Person Meyer, Ron (InfanDx 201010–202101 CEO + Founder LEFT 202102)
  Person 2 Roehrig, Klaus (Bamed MAM Group 201904 Co-Owner)

InfanDx took a decisive step in its financial development to receive up to 5.3 Mio. EUR capital investment in a milestone structured deal. As new investors Bamed MAM Group and CVG Capital GmbH providing market knowhow alongside financial resources. Additionally existing shareholders LSI-Pre-Seed-Fonds GmbH and Arnika Beteiligungen GmbH co-invested in the current capital increase.

“We are very happy that the extremely positive results from our confirmatory clinical study concluded just last year provided us with such striking arguments to convince our new shareholders” explained InfanDx CEO Ron Meyer. The new funds shall serve to complete the ongoing clinical validation study involving 500 patients and shall support the technical development of the new Point-of-Care test format. “Due to our research in cooperation with leading universities, we are well aware of the medical need for the test developed by InfanDx. We are highly excited to see the economic potential of InfanDx and as well the expected medical breakthrough with benefit to newborns on a truly global scale” stated Klaus Roehrig, Co-Owner of Bamed MAM Group. Dr. Joerg Fregien, Chairman and representative of the currently largest investor LSI adds “This successful financing round is another strong confirmation of the outstanding market relevance of projects Life Science Inkubator in Bonn currently engages in.”

This test, as first of its kind, will allow the early and reliable diagnosis of oxygen deficit during birth (perinatal asphyxia) and subsequent brain damage. It will fill a critical gap to enable the existing therapeutic approaches to reach early enough and help many affected children who are today overlooked and doomed to life long disability. Worldwide and each year >1 mio. babies suffer from NE, which makes it within the delivery period the largest single cause for life long morbidity. The biomarkers developed by the InfanDx-project will be the first diagnostic tool to reliably identify the babies in need early enough within the therapeutic time-window.

InfanDx AG develops products based on biomarkers derived from metabolomics research. Lead product is a diagnostic test on perinatal asphyxia (oxygen deficit during birth) and thereof resulting brain damage. Furthermore, InfanDx holds patent applications for intended following products.

Bamed MAM Group is a leading manufacturer of baby products. Bamed MAM excels in optimally balancing design and function. To achieve this collaboration with physicians, scientists, midewifes and parents enables the fulfilment of highest demands and ensures the best conditions for a perfect start into life.

Questions pls. to

InfanDx AG
Ron Meyer (CEO)
Balthasarstr. 18
50670 Köln
T: +49 (0) 221 30089783
Fax: +49 (0) 221 2851975

Record changed: 2019-05-01


Picture [iito] Plain Stupid Simple 650x80px

More documents for InfanDx AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top